Abstract

PUGA L, Bárbara; BUSTAMANTE K, Katherinne; MOLINA E, Javiera  and  ANDRADE M, Alejandro. Intensive chemotherapy for Burkitt lymphoma in HIV positive patients. Rev. méd. Chile [online]. 2015, vol.143, n.12, pp.1505-1511. ISSN 0034-9887.  http://dx.doi.org/10.4067/S0034-98872015001200001.

Background: Burkitt lymphoma has a low incidence, is highly aggressive, may be endemic, sporadic or associated with immunodeficiency and it has a high frequency of extranodal involvement. Overall and relapse free survival in HIV patients is 72 and 71% respectively. However, the current protocol in Chile considers a positive HIV serology as an exclusion criterion for intensive chemotherapy. Aim: To analyze the response to Burkitt lymphoma treatment among HIV positive patients. Material and Methods: All HIV positive patients with a Burkitt lymphoma treated using PANDA protocol in a public hospital were analyzed. Results: Eight male patients aged between 25 and 43 years, 63% in stage IV, were analyzed. All patients received an intensified chemotherapy regime, three of them without Rituximab. Complete remission was achieved in 87%. One patient was refractory to treatment and one patient relapsed at 5 months and died. Overall and relapse free survival were 58 and 60% respectively. All patients had episodes of high risk febrile neutropenia, but it did not cause deaths. Conclusions: In this group of HIV patients, intensive chemotherapy for Burkitt lymphoma had a high degree of effectiveness with a low relapse rate and high cure rate.

Keywords : Antineoplastic protocols; Burkitt lymphoma; HIV.

        · text in Spanish     · Spanish ( pdf )